Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

NCT01132664 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

72

Enrollment

INDUSTRY

Sponsor class

Stopped Due to the rare patient population and challenges to enroll patients.

Conditions

Metastatic Breast Cancer
HER2+ Breast Cancer

Interventions

DRUG: BKM120
DRUG: Trastuzumab
DRUG: Capecitabine

Sponsor

Novartis Pharmaceuticals